FDA rejects atrial fibrillation drug, aspirin does not benefit black patients — top stories in cardiology
Click Here to Manage Email Alerts
News that an FDA panel voted against the approval of vernakalant for the rapid conversion of recent-onset atrial fibrillation was among the top stories in cardiology last week.
Another top story was about a study that indicated low-dose aspirin failed to prevent ischemic cardiac death in black adults.
Read more below.
FDA panel does not recommend approval of vernakalant for atrial fibrillation
Citing safety concerns, the Cardiovascular and Renal Drug Advisory Committee of the FDA voted 2-11 against approval of vernakalant for the rapid conversion of recent-onset atrial fibrillation. Read more.
Low-dose aspirin fails to prevent ischemic cardiac death in black adults
There is no evidence that low-dose aspirin helps prevent ischemic cardiac death among black adults, researchers reported in the Journal of the American Heart Association. Read more.
AHA: Geriatric syndromes affect care of older patients in cardiac ICU
Despite older patients receiving the care they need in cardiac ICUs, they may experience worsening of geriatric conditions such as cognitive impairments and frailty, according to an American Heart Association scientific statement published in Circulation. Read more.
Omecamtiv mecarbil may improve diastolic function, pulmonary pressures in heart failure
Omecamtiv mecarbil, a selective cardiac myosin activator, improved diastolic function and pulmonary pressures without worsening diastolic filling in patients with chronic heart failure and reduced systolic function, according to data presented at the American Heart Association Scientific Sessions. Read more.
Type 2 myocardial infarction confers elevated risk for death within 1-year follow-up
Findings presented at the American Heart Association Scientific Sessions indicate that patients with type 2 myocardial infarction are at greater risk for recurrent CV events and death within the first year of follow-up compared with patients experiencing type 1 myocardial infarction. Read more.